BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
Amount Raised
$1.25 Billion
Round Type
Venture
Palo AltoBiotechnologyHealth CareTherapeuticsInvestors
Description
BridgeBio Pharma, Inc. secures up to $1.25 billion of capital from Blue Owl and CPP Investments to accelerate the development and launch of genetic medicines, including a $500 million cash raise, a $450 million credit facility, and the possibility of additional incremental facilities of up to $300 million of credit to support strategic pipeline expansion and acceleration. The financing allows BridgeBio to enter 2024 well capitalized to launch acoramidis and continue to accelerate its industry-leading genetic medicine R&D engine.
Quick answer
BridgeBio raised $1.25 Billion in a funding round, dated January 22, 2024. Investors: Canada Pension Plan Investment Board and Blue Owl Capital. BridgeBio is based in Palo Alto, California, United States.
- How much did BridgeBio raise?
- BridgeBio raised $1.25 Billion in a funding round on January 22, 2024.
- Who invested in BridgeBio?
- Canada Pension Plan Investment Board and Blue Owl Capital are named as investors in this round.
- What does BridgeBio do?
- BridgeBio Oncology Therapeutics (BBOT) has launched with a $200m private financing round, aiming to expedite the development of the company’s precision oncology pipeline and focusing on new cancer treatments.
- Where is BridgeBio based and how big is it?
- BridgeBio is based in Palo Alto, California, United States. Fundz records about 730 employees.
- Who are the decision-makers at BridgeBio?
- Fundz holds 1 contact at BridgeBio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as BridgeBio that raised within 45 days of this round, from Fundz verified event records.
- Adipo Therapeutics raised $1.9M (Seed) on March 7, 2024.
- bioAffinity Technologies raised $2.6M (Seed) on March 6, 2024.
- Azora Therapeutics, Inc. (DE) raised $288K (Seed) on March 6, 2024.
- Capstan Therapeutics raised $87M on March 5, 2024.
- Parabilis Medicines raised $145M (Series E) on March 1, 2024.
- Crinetics Pharmaceuticals raised $350M on March 1, 2024.
Who to call at BridgeBio, and when
A new round usually means BridgeBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day BridgeBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BridgeBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BridgeBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BridgeBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
BridgeBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.